Overview

Evaluation of Pharmacokinetics , Safety, Tolerability and Pharmacodynamics of Biocon Insulin Tregopil

Status:
Recruiting
Trial end date:
2022-01-25
Target enrollment:
Participant gender:
Summary
Multi-centre, open label, multiple ascending dose trial in patients with type 1 diabetes mellitus
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Biocon Limited
Collaborators:
Juvenile Diabetes Research Foundation
Profil Institut für Stoffwechselforschung GmbH
Treatments:
Insulin
Insulin Aspart
Insulin, Globin Zinc